UroGen Pharma Ltd. has grown revenue 38% a year over three years and 43% a year over five. Revenue growth, 3-year annual rate: +38% (Biotechnology median +17%). Revenue growth, 5-year rate: +43%, growth has slowed since the five-year average. Years of annual history on file: 11, FY2015 to FY2025, as filed.

URGNUroGen Pharma Ltd.

Healthcare

$36.82+105% 1Y

$36.82

$16.4252 weeks$50.29

Is it growing?

Good

Growing: revenue growing +100% year on year and operating margin widening (+86.5 points).

2 good, 1 without data

Revenue trend+100% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +43% a year.

Margin direction+86.5 points operating

Trailing-twelve-month operating margin, -47.4% now against -133.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is URGN growing?

UroGen Pharma Ltd. has grown revenue 38% a year over three years and 43% a year over five.

+38%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +43%
Revenue growth, 5-year rate · +38% over three · growth has slowed since the five-year average
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed

Details›